Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Developing stem cell therapies for juvenile and adult-onset Huntington's disease

Fink KD., Deng P., Torrest A., Stewart H., Pollock K., Gruenloh W.

Narrative Review, published in Regen Med (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Regen Med (2015)
Reported sample size
—
Source database
Europe PMC
PMID
26237705
PMCID
PMC6785015
DOI
10.2217/rme.15.25
Citations
34

Abstract (original English)

Stem cell therapies have been explored as a new avenue for the treatment of neurologic disease and damage within the CNS in part due to their native ability to mimic repair mechanisms in the brain. Mesenchymal stem cells have been of particular clinical interest due to their ability to release beneficial neurotrophic factors and their ability to foster a neuroprotective microenviroment. While early stem cell transplantation therapies have been fraught with technical and political concerns as well as limited clinical benefits, mesenchymal stem cell therapies have been shown to be clinically beneficial and derivable from nonembryonic, adult sources. The focus of this review will be on emerging and extant stem cell therapies for juvenile and adult-onset Huntington's disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Central Nervous SystemNeuronsMesenchymal Stem CellsImmune SystemAnimalsAnimals, Genetically ModifiedHumansHuntington DiseaseDisease ProgressionNerve Growth Factors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.